en
Nieuwsbrief
Cases

Indigo Diabetes

  • Life Sciences & Care
  • Portfolio Life Sciences & Care
  • Life sciences & care

Indigo, a spin-off of Ghent University (UGent) and imec, is using pioneering photonics technologies to develop a glucose sensor without a lancing pen. The company is developing a revolutionary, high-tech sensor that doctors will insert subcutaneously, continuously monitoring blood sugar levels.

The development of an implantable sensor replaces multiple finger pricks a day and will greatly improve the quality of life for diabetics and their caregivers. In addition, the sensor technology allows simultaneous monitoring of multiple biologically relevant metabolites. The company is based in Ghent, where it has access to Ugent’s Photonics Research Group and the NB-Photonics consortium, a leading European academic consortium specialising in photonics.

Partners in ambition at Indigo Diabetes

In an initial capital round in 2016, Indigo Diabetes raised €7 million from an international investment syndicate led by Thuja Capital Healthcare Fund II (Netherlands) and PMV (Belgium). Other members of the syndicate include Sensinnovat, Parana Management Corp, Qbic Arkiv Fund, Fidimec, SOFI, Manuardeo and Capricorn ICT Arkiv. This funding was used to further develop the multi-biomarker sensor for people with diabetes.

In 2020, Indigo completed a Series B capital round of €38 million. This investment will allow the company to launch clinical trials with test subjects in Europe and the US after promising preclinical results. The capital round was led by Fund+, with the participation of Ackermans & van Haaren, imec.xpand, Capricorn Digital Growth Fund, QBICII, Titan Baratto and Series A investors, including PMV.